Piedmont Investment Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Piedmont Investment Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,657	Closed	-$581K	–	81
2020 Q1	$581K	Hold	1,657	–	–	0.02%	411
2019 Q4	$613K	Sell	1,657 -286	-15%	-$101K	0.02%	454
2019 Q3	$647K	Sell	1,943 -8	-0.4%	-$2.61K	0.03%	429
2019 Q2	$610K	Buy	+1,951	New	+$584K	0.02%	459
2018 Q3	–	Sell	-4,815	Closed	-$1.39M	–	1178
2018 Q2	$1.39M	Sell	4,815 -1	-0%	-$276	0.07%	274
2018 Q1	$1.2M	Buy	+4,816	New	+$1.23M	0.03%	308
2016 Q2	–	Sell	-5	Closed	-$684	–	640
2016 Q1	$684	Hold	5	–	–	﹤0.01%	386
2015 Q4	$693	Hold	5	–	–	﹤0.01%	391
2015 Q3	$671	Hold	5	–	–	﹤0.01%	393
2015 Q2	$753	Buy	+5	New	+$715	﹤0.01%	403

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Piedmont Investment Advisors's BIO Position: Q2 2020 in Review

Piedmont Investment Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2020, closing a stake of 1,657 shares — an estimated $581K sold.

Piedmont Investment Advisors first reported a position in BIO in Q2 2015 and held it in 10 quarters. The position peaked at $1.39M in Q2 2018. 470 funds tracked by Wall St. Rank hold BIO as of Q2 2020.

Piedmont Investment Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2020 after selling out during the quarter.
Piedmont Investment Advisors sold 1,657 Bio-Rad Laboratories Class A shares in Q2 2020, an estimated $581K.
Piedmont Investment Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2015 and held it in 10 quarters.
Piedmont Investment Advisors's Bio-Rad Laboratories Class A position peaked at $1.39M in Q2 2018.
470 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2020.

Based on Piedmont Investment Advisors's 13F filing for Q2 2020.